Abstract:Chemotherapeutic resistance via the mechanism of competitive release of resistant tumor cell subpopulations is a major problem associated with cancer treatments and one of the main causes of tumor recurrence. Often, chemoresistance is mitigated by using multidrug schedules (two or more combination therapies) that can act synergistically, additively, or antagonistically on the heterogeneous population of cells as they evolve. In this paper, we develop a three-component evolutionary game theory model to design two-drug adaptive schedules (timing and dose levels associated with C 1 ( t ) and C 2 ( t )) that mitigate chemoresistance and delay tumor recurrence in an evolving collection of tumor cells with two resistant subpopulations: R 1 (sensitive to drug 1, resistant to drug 2), and R 2 (sensitive to drug 2, resistant to drug 1). A key parameter, e , takes us from synergistic ( e > 0), to additive ( e = 0), to antagonistic ( e < 0) drug interactions. In addition to the two resistant populations, the model includes a population of chemosensitive cells, S that have higher baseline fitness but are not resistant to either drug. Using the nonlinear replicator dynamical system with a payoff matrix of Prisoner’s Dilemma (PD) type (enforcing a cost to resistance), we investigate the nonlinear dynamics of the three-component system ( S, R 1 , R 2 ), along with an additional tumor growth model whose growth rate is a function of the fitness landscape of the tumor cell populations. We show that antagonistic drug interactions generally result in slower rates of adaptation of the resistant cells than synergistic ones, making them more effective in combating the evolution of resistance. We then design closed loops in the three-component phase space by shaping the fitness landscape of the cell populations (i.e. altering the evolutionary stable states of the game) using appropriately designed time-dependent schedules (adaptive therapy), altering the dosages and timing of the two drugs using information gleaned from constant dosing schedules. We show that the bifurcations associated with the evolutionary stable states are transcritical, and we detail a typical antagonistic bifurcation that takes place between the sensitive cell population S and the R 1 population, and a synergistic bifurcation that takes place between the sensitive cell population S and the R 2 population for fixed values of C 1 and C 2 . These bifurcations help us further understand why antagonistic interactions are more effective at controlling competitive release of the resistant population than synergistic interactions in the context of an evolving tumor.

Evolutionary Analysis of Replicator Dynamics about Anti-Cancer Combination Therapy

Bayesian neural networks, decision boundary, explainable artificial intelligence, machine learning, model uncertainty, posterior predictive check, prior probability, probabilistic programming, scatter plot, variational posterior distribution

Mathematical modeling and dynamic analysis for cancer resistance incorporating persister cells

The role of synergy and antagonism in designing multidrug adaptive chemotherapy schedules

Evolutionary rescue model informs strategies for driving cancer cell populations to extinction

Exploiting evolution to treat drug resistance: combination therapy and the double bind

Stochastic competitive release and adaptive chemotherapy

Theoretical understanding of evolutionary dosing following tumor dynamics

Discrete and continuum phenotype-structured models for the evolution of cancer cell populations under chemotherapy

A SIMPLE EVOLUTIONARY MODEL FOR CANCER CELL POPULATION AND ITS IMPLICATIONS ON CANCER THERAPY

Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory

Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates

The Optimization of Combination Chemotherapy Schedules in the Presence of Drug Resistance

Modeling multi-mutation and drug resistance: analysis of some case studies

[Co-evolutionary analysis on strategy for therapy of spreading cancer]

Mathematical modeling of combined therapies for treating tumor drug resistance

Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies

Are Adaptive Chemotherapy Schedules Robust? A Three-Strategy Stochastic Evolutionary Game Theory Model

Mathematical modeling and bifurcation analysis for a biological mechanism of cancer drug resistance

Personalized cancer treatment strategies incorporating irreversible and reversible drug resistance mechanisms

Combination Therapy of Cancer with Cancer Vaccine and Immune Checkpoint Inhibitors: A Mathematical Model